%20found%20that%20not%20all%20patients%20share%20the%20same%20metabolic%20profile,%20meaning%20their%20cells%20process%20energy%20differently.%20In%20particular,%20one%20s...){kind=link}
Nicotinamide Riboside and Pterostilbene Therapy Improves Cell Metabolism and Shows Promise in ALS: Preclinical Findings
Synopsis
Researchers studying amyotrophic lateral sclerosis (ALS) found that not all patients share the same metabolic profile, meaning their cells process energy differently. In particular, one subgroup of ALS patients (called sALS1) showed unique changes in metabolism compared to others. When treated with EH301, a combination of nicotinamide riboside (NR)—a vitamin B3 derivative—and pterostilbene, these cells showed improved energy balance and protection against stress by activating anti-inflammatory and antioxidant pathways. The study also identified specific genes and metabolic markers linked to disease severity and progression, which EH301 appeared to modify. These findings suggest that personalized metabolic treatments using NAD+ boosters like NR could help slow ALS progression in certain patient groups.
Journal
Human Molecular Genetics